期刊文献+

华法林与阿司匹林对低危非瓣膜病心房颤动患者抗栓疗效比较 被引量:6

暂未订购
导出
摘要 目的:通过华法林与阿司匹林对低危非瓣膜病心房颤动(NVAF)的疗效及安全性比较,以明确低危NVAF患者抗栓治疗的最佳选择。方法:根据国际指南中关于NVAF血栓栓塞高危因素的建议,明确低危NVAF患者,入选的低危NVAF患者随机分为华法林组(目标INR1.7~2.5)与阿司匹林组(150 mg/d),比较华法林组与阿司匹林组脑栓塞和出血事件的发生率。结果:华法林组仅1例(1.39%)发生脑栓塞,阿司匹林组3例(3.70%)发生脑栓塞,华法林组脑栓塞发生率低于阿司匹林组,但经统计学检验差异无统计学意义(P>0.05)。华法林组3例(4.17%)发生出血,阿司匹林组2例(2.47%),华法林组出血发生率高于阿司匹林组,但经统计学检验差异也无统计学意义(P>0.05)。结论:低危NVAF患者,华法林与阿司匹林疗效相似,但由于华法林需严密监测INR给临床用药带来不便,而阿司匹林具有有效、安全性好、服用方便、价格低廉等优点,值得推荐。
出处 《吉林医学》 CAS 2012年第8期1625-1626,共2页 Jilin Medical Journal
  • 相关文献

参考文献5

  • 1孙艺红.华法林的临床应用与监测[J].中国实用内科杂志,2007,27(9):657-660. 被引量:26
  • 2Kannel WB,Wolf PA,Benjamin EJ,et al.Prevalence incidence prognosis,and predisposing conditions for atrial fibrillation:population-based estimates[J].Am J Cardiol,1998,82 (8A):2N.
  • 3戚文航.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志,2003,31(12):913-916. 被引量:381
  • 4Munger TM,Packer DL,Hummill SC,et al.A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County Minnesota.1953 - 1989[J].Circulation,1993,87(8):886.
  • 5The Atrial Fibrillation Investigators.The efficacy of aspirin in patients with atrial fibrillation:analysis of pooled date from 3randomized trials[J].Arch Intern Med,1997,157 (12):1237.

二级参考文献9

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:163
  • 2Hirsh J,Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation. American Heart Association/American College of Cardiology. Foundation guide to warfarin therapy[ J ]. J Am Coll Cardiol,2003,41 ( 9 ) : 1633 - 1652.
  • 3Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K dependent clotting factors[ J ]. J Clin Invest, 1993,92:2131 - 2140.
  • 4Tham LS,Goh BC, Nafziger A, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 [ J ]. Clin Pharmacol Ther,2006,80 ( 4 ) :346 - 355.
  • 5Eekhoff CD,Didomenieo RJ,Shapiro NL. Initiating warfarin therapy :5 mg versus 10 mg [ J ]. Ann Pharmacother, 2004,38 ( 12 ) : 2115 -2121.
  • 6Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international nornlalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized, controlled trial [ J ]. Ann Intern Med, 2002,137 : 251 - 254.
  • 7Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery, disease: a meta-analysis [ J]. JAMA, 1999,282 : 2058 - 2067.
  • 8Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest, 2004,126 ( 3 Suppl ) :457 - 482.
  • 9Carmegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valve prostheses:the Leiden artificial valve and anticoagulation study[J].N Engl J Med, 1995,333:11 - 17.

共引文献404

同被引文献31

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部